Proteins, which are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases, are called as protein therapeutics. Therapeutic protein drugs are one of the important classes of medicines that are administered for treating an array of different diseases including infectious diseases, cancer, and others. These drugs possess the significant potential to improve human health. Protein based therapies have found a leading place in the biopharmaceutical industry since the launch of the human insulin product. It is shown that proteins are crucial for maintaining a healthy lifestyle and for the people, whose bodies cannot breakdown or produce some essential proteins naturally, are prone to several diseases.

Market Overview

Since the introduction of human insulin, the first recombinant protein therapeutic, the protein therapeutics market has revolutionized tremendous growth. Due to its increased usage, the market influences the huge potential for future growth and is estimated that it may reach the mark of US$ 208 Billion by the end of 2020. Further, the launch of new products is also likely to propel the market growth. A large number of market players have been developing monoclonal antibodies (mAbs). The increased usage of mAbs in various therapies like radio-immunotherapy and antibody-directed enzyme prodrug therapy are going to drive the growth of the market. Additionally, mAbs are also used in the formulation of biopharmaceutical drugs for the treatment of different diseases including cancer and ulcerative colitis, which will also aid in the market’s growth in the coming years.

For instance, the rising global prevalence of diabetes, a disease that occurs due to dysfunctional production or processing of the insulin protein, has led to significant developments in the global protein therapeutics market in the past few years. The demand for protein therapeutics has increased greatly, due to the increase in the prevalence of chronic diseases and related development of plasma-derived therapies. Further, the surge in awareness with respect to protein therapeutics among the population is going to boost the therapeutic market growth. Anyway, high costs associated with developing therapeutic proteins and stringent government regulations towards therapeutic proteins hinder the growth of the market. Conversely, adoption of protein therapeutics for novel procedures and the developing countries untapped potential are anticipated to provide profitable opportunities to the market players.

Key Developments

Sanofi can use Biomunex Pharmaceuticals’ proprietary BiXAb® platform to generate and optimize bi- and multi-specific antibodies for developing new treatments in immuno-oncology and other therapeutic areas, Biomunex said on Jan 2019.

Amgen and Molecular Partners, a clinical-stage biotech company pioneering the use of DARPin® therapeutics, in Dec 2018, announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).

Segmentation

The protein therapeutics industry is segmented based on protein therapeutic modalities, product, application, and geography.

Based on protein therapeutic modalities: Protein diagnostics, protein vaccines, protein therapeutics with special targeting activity, and protein therapeutics with enzymatic or regulatory activity.

Based on the product: The therapeutic market is divided into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle stimulating hormone. Monoclonal antibodies accounted for the largest share in the global market, due to the necessity and applicability of these antibodies in the treatment of different chronic disorders.

Based on Geography: This market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America holds for the highest revenue in the protein therapeutics market in 2016. Asia-Pacific occupied high market potential, owing to an increase in awareness about protein therapeutics-based treatments and a rise in protein therapeutics applications.

Report Description: The report covers in-depth analysis on Global Protein Therapeutics Market. The report assesses the Protein Therapeutics pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Metabolic disorders, hematological disorders, immunologic disorders, cancer, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.

The report includes in-depth company profiles of key players in Global Protein Therapeutics Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.

The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.

Scope:

Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Protein Therapeutics Market.

Provides a complete overview of market segments and the regional outlook of Global Protein Therapeutics Market.

Provides in-depth coverage of key news related to Global Protein Therapeutics Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:

Data Collation (Primary & Secondary)

In-house Estimation (Based on proprietary databases and Models)

Market Triangulation

Forecasting

Market-related information is assembled from both primary and secondary sources.

Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.

Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.